Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Transfer of Samples from Satellite Clinics – V 2.0

Posted on By

BA-BE Studies: SOP for Transfer of Samples from Satellite Clinics – V 2.0

Standard Operating Procedure for Transfer of Samples from Satellite Clinics in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/113/2025
Supersedes SOP/BA-BE/113/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for the transfer of clinical samples (e.g., blood, plasma) from satellite clinic sites to the central laboratory in a secure and temperature-controlled manner to ensure sample integrity and traceability in BA/BE studies.

2. Scope

This SOP applies to clinical research and logistics personnel involved in the packaging, documentation, transportation, and handover of samples from

satellite collection clinics to the main analytical facility.

3. Responsibilities

  • Satellite Clinic Coordinator: Ensures proper labeling, packaging, and documentation prior to dispatch.
  • Courier/Transport Personnel: Transfers the samples in validated transport containers maintaining cold chain.
  • Central Lab Receiver: Verifies receipt, condition, temperature status, and signs chain of custody log.
  • QA Officer: Reviews transport records and investigates any deviations.
See also  BA-BE Studies: SOP for Study Initiation Checklist - V 2.0

4. Accountability

The Clinical Operations Manager and Laboratory Head are accountable for ensuring compliant and traceable transport of samples from satellite clinics to the central storage or processing site.

5. Procedure

5.1 Pre-Shipment Preparation

  1. Use Annexure-1: Sample Dispatch Checklist to verify correct labeling, primary packaging, and number of samples.
  2. Place labeled tubes in leak-proof, pre-chilled secondary containers with absorbent material.
  3. Pack into validated tertiary containers with gel packs/dry ice as per required temperature (-20°C or -70°C).

5.2 Documentation

  1. Complete the following before dispatch:
    • Annexure-2: Sample Transfer Manifest
    • Annexure-3: Chain of Custody Log
    • Attach copy of Sample Reconciliation Sheet
  2. Seal tertiary container with tamper-evident tape.

5.3 Transport and Monitoring

  1. Use validated courier with cold chain logistics experience.
  2. Affix “Biological Samples – Handle with Care” and temperature requirement label.
  3. Place a temperature monitoring device inside each shipment (Annexure-4: Temperature Logger Report).
See also  BA-BE Studies: SOP for Supervision of Dosing Procedures - V 2.0

5.4 Receipt at Central Lab

  1. On receipt:
    • Inspect container integrity
    • Verify temperature range compliance
    • Cross-check manifest and actual samples
  2. Document findings in Annexure-5: Sample Receipt Form.

5.5 Deviations and CAPA

  1. If temperature excursions or tampering is observed:
    • Segregate affected samples
    • Document in deviation form (Annexure-6)
    • Initiate CAPA in coordination with QA

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Sample Dispatch Checklist – Annexure-1
  2. Sample Transfer Manifest – Annexure-2
  3. Chain of Custody Log – Annexure-3
  4. Temperature Logger Report – Annexure-4
  5. Sample Receipt Form – Annexure-5
  6. Deviation Form and CAPA Log – Annexure-6

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • WHO Technical Report Series on Sample Transport

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department
See also  BA-BE Studies: SOP for Dose Selection Criteria for BA/BE Studies - V 2.0

11. Annexures

Annexure-1: Sample Dispatch Checklist

Item Status Remarks
Labels verified Yes Confirmed
Temperature packs Yes Frozen

Annexure-2: Sample Transfer Manifest

Volunteer ID Timepoint Tube Count Volume
VOL-113-008 2hr 2 2.5 mL each

Annexure-3: Chain of Custody Log

Date From To Signature Remarks
17/04/2025 Satellite Clinic A Central Lab Signed Frozen condition maintained

Annexure-4: Temperature Logger Report

Attached PDF generated by TempSure Logger. Range: -21.2°C to -23.5°C

Annexure-5: Sample Receipt Form

Received By Date Condition Temperature Remarks
Ajay Verma 17/04/2025 Good -22.5°C All samples intact

Annexure-6: Deviation Form and CAPA Log

Date Deviation Root Cause CAPA Closed By
16/04/2025 Temperature logger not activated Human error Retraining of site staff QA Head

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP Release GCP Compliance QA Head
17/04/2025 2.0 Added chain of custody and validated packaging protocols Logistics Audit QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Integration with Product Development Team – V 2.0
Next Post: API Manufacturing: SOP for Testing of Reaction Completion by TLC – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version